Peptides · Longevity & Cellular Health

SLU-PP-332

Exercise mimetic

Preclinical (animal studies only)

Not a peptide — a small-molecule ERR agonist.

The 'exercise in a pill' headline-maker: a small molecule (not a peptide) that activates the same energy-metabolism receptors exercise does. Every result so far — increased endurance, fat loss without diet change — comes from mice.

At a glance

  • Activates estrogen-related receptors that drive muscle metabolism
  • Increased endurance and fat metabolism in mouse studies
  • Zero human data — safety entirely unknown
  • Prohibited in sport via WADA's S0 catch-all; detection methods published 2026

How it works

SLU-PP-332 activates estrogen-related receptors (ERRα/β/γ), master regulators of mitochondrial energy metabolism in muscle. Activating them mimics part of the adaptive response muscles make to endurance training.

What the research shows

In mouse studies it increased running endurance, muscle oxidative fibres, and fat metabolism — obese mice lost fat without eating less. There are no human trials of any kind; safety in people is entirely unknown.

Regulatory status

Australia

It has no entry in the Poisons Standard — the nearby SR9009 listing covers REV-ERB agonists, a different receptor family — but with no approval anywhere and no ARTG listing, it cannot lawfully be supplied for human therapeutic use in Australia.

Worldwide

Preclinical worldwide — it has never entered human trials and no regulator has reviewed it. WADA's S0 catch-all prohibits unapproved substances in sport, and anti-doping laboratories published detection methods for it in 2026. Development focus has shifted to an orally bioavailable successor, SLU-PP-915.

Latest SLU-PP-332 articles

This is general information, not medical advice. retatrutide.net.au is an independent publication. Unless stated otherwise above, this compound is not an approved medicine in Australia, and this page does not endorse or facilitate its use. Speak to a registered health practitioner about any treatment decision.

Stay informed

Be first to know.
When it reaches Australia.

Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:

  • The latest clinical trial results and news from Eli Lilly
  • Updates on TGA regulatory progress in Australia
  • How and where to access Retatrutide when it becomes available
  • Occasional information from retatrutide.net.au and our affiliated partners
TGA review expected 2027 — subscribers hear the moment the status changes.

Get the free guide + updates

Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.

Sign up now
SLU-PP-332 — Research, Evidence & Australian Status | Retatrutide Australia